, NURS 676 Advanced Pharmacology Midterm Exam Master Study Guide 100%
Original High Density Practice Evaluation Matrix West Coast University Summer
Fall Term Performance Optimization Evaluation Blueprint
1. A 58-year-old male with chronic primary hypertension requires initiate drug
therapy. He has a concurrent history of severe type 2 bronchospastic asthma.
Which beta-blocker is safest to avoid inducing severe bronchoconstriction?
A) Propranolol
B) Nadolol
C) Metoprolol
D) Timolol
Rationale: Metoprolol is a cardioselective beta-1 adrenergic antagonist. Unlike
non-selective beta-blockers (Propranolol, Nadolol, Timolol) that block both
beta-1 and beta-2 receptors, low-dose metoprolol selectively blocks beta-1
receptors in the heart, minimizing the risk of inducing severe
bronchoconstriction via respiratory beta-2 receptor blockade.
2. What is the fundamental cellular mechanism of action of Angiotensin-
Converting Enzyme (ACE) inhibitors like Lisinopril?
A) Directly blocking the AT1 receptors in vascular smooth muscle
B) Inhibiting the conversion of Angiotensin I to Angiotensin II in the lungs
C) Preventing the release of renin from the juxtaglomerular apparatus
D) Promoting the direct cellular excretion of aldosterone from the adrenal
cortex
Rationale: ACE inhibitors block the angiotensin-converting enzyme, which
prevents the conversion of angiotensin I to the potent vasoconstrictor
angiotensin II. This leads to reduced systemic vascular resistance and a
decrease in aldosterone secretion, reducing blood pressure.
3. A patient taking Warfarin for atrial fibrillation is prescribed Amiodarone. What
pharmacokinetic interaction should the clinician anticipate regarding Warfarin
dosing?
A) Amiodarone inhibits CYP2C9 metabolism, necessitating a down-titration of
Warfarin
B) Amiodarone induces CYP3A4, requiring an increase in Warfarin dosing
C) Amiodarone binds directly to albumin, displacing Warfarin and accelerating
renal clearance
, D) Amiodarone neutralizes the intrinsic pathway mechanism of Warfarin
entirely
Rationale: Amiodarone is a potent inhibitor of the cytochrome P450 enzyme
CYP2C9, which is the primary metabolic pathway for S-warfarin. This inhibition
dramatically increases serum concentrations of Warfarin, elongating the INR
and necessitating an empirical reduction in the Warfarin dose by 30% to 50%.
4. Which pharmacological parameter describes the time required for the
systemic concentration of a drug to decrease by exactly 50% within the human
body?
A) Volume of distribution (\(V_{d}\))
B) Bioavailability (\(F\))
C) Elimination half-life (\(t_{1/2}\))
D) Clearance rate (\(Cl\))
Rationale: The elimination half-life (\(t_{1/2}\)) is a constant pharmacokinetic
value defining the absolute time needed for the total plasma concentration of a
drug to be reduced by half via metabolic transformation or excretion.
5. A patient presents to the emergency department with a severe, dry, hacking
cough and angioedema of the lips. Which medication class is most commonly
associated with these class-specific adverse effects?
A) Angiotensin-Converting Enzyme (ACE) Inhibitors
B) Angiotensin Receptor Blockers (ARBs)
C) Calcium Channel Blockers (CCBs)
D) Thiazide Diuretics
Rationale: ACE inhibitors prevent the breakdown of bradykinin and substance
P by kininase II. The systemic accumulation of bradykinin in the upper
respiratory tract and cutaneous tissues causes the characteristic dry cough
and life-threatening angioedema.
6. What is the primary therapeutic mechanism of action of HMG-CoA reductase
inhibitors (Statins) within hepatocytes?
A) Directly blocking cholesterol reabsorption in the brush border of the small
intestine
B) Activating peroxisome proliferator-activated receptor alpha (PPAR-alpha)
Original High Density Practice Evaluation Matrix West Coast University Summer
Fall Term Performance Optimization Evaluation Blueprint
1. A 58-year-old male with chronic primary hypertension requires initiate drug
therapy. He has a concurrent history of severe type 2 bronchospastic asthma.
Which beta-blocker is safest to avoid inducing severe bronchoconstriction?
A) Propranolol
B) Nadolol
C) Metoprolol
D) Timolol
Rationale: Metoprolol is a cardioselective beta-1 adrenergic antagonist. Unlike
non-selective beta-blockers (Propranolol, Nadolol, Timolol) that block both
beta-1 and beta-2 receptors, low-dose metoprolol selectively blocks beta-1
receptors in the heart, minimizing the risk of inducing severe
bronchoconstriction via respiratory beta-2 receptor blockade.
2. What is the fundamental cellular mechanism of action of Angiotensin-
Converting Enzyme (ACE) inhibitors like Lisinopril?
A) Directly blocking the AT1 receptors in vascular smooth muscle
B) Inhibiting the conversion of Angiotensin I to Angiotensin II in the lungs
C) Preventing the release of renin from the juxtaglomerular apparatus
D) Promoting the direct cellular excretion of aldosterone from the adrenal
cortex
Rationale: ACE inhibitors block the angiotensin-converting enzyme, which
prevents the conversion of angiotensin I to the potent vasoconstrictor
angiotensin II. This leads to reduced systemic vascular resistance and a
decrease in aldosterone secretion, reducing blood pressure.
3. A patient taking Warfarin for atrial fibrillation is prescribed Amiodarone. What
pharmacokinetic interaction should the clinician anticipate regarding Warfarin
dosing?
A) Amiodarone inhibits CYP2C9 metabolism, necessitating a down-titration of
Warfarin
B) Amiodarone induces CYP3A4, requiring an increase in Warfarin dosing
C) Amiodarone binds directly to albumin, displacing Warfarin and accelerating
renal clearance
, D) Amiodarone neutralizes the intrinsic pathway mechanism of Warfarin
entirely
Rationale: Amiodarone is a potent inhibitor of the cytochrome P450 enzyme
CYP2C9, which is the primary metabolic pathway for S-warfarin. This inhibition
dramatically increases serum concentrations of Warfarin, elongating the INR
and necessitating an empirical reduction in the Warfarin dose by 30% to 50%.
4. Which pharmacological parameter describes the time required for the
systemic concentration of a drug to decrease by exactly 50% within the human
body?
A) Volume of distribution (\(V_{d}\))
B) Bioavailability (\(F\))
C) Elimination half-life (\(t_{1/2}\))
D) Clearance rate (\(Cl\))
Rationale: The elimination half-life (\(t_{1/2}\)) is a constant pharmacokinetic
value defining the absolute time needed for the total plasma concentration of a
drug to be reduced by half via metabolic transformation or excretion.
5. A patient presents to the emergency department with a severe, dry, hacking
cough and angioedema of the lips. Which medication class is most commonly
associated with these class-specific adverse effects?
A) Angiotensin-Converting Enzyme (ACE) Inhibitors
B) Angiotensin Receptor Blockers (ARBs)
C) Calcium Channel Blockers (CCBs)
D) Thiazide Diuretics
Rationale: ACE inhibitors prevent the breakdown of bradykinin and substance
P by kininase II. The systemic accumulation of bradykinin in the upper
respiratory tract and cutaneous tissues causes the characteristic dry cough
and life-threatening angioedema.
6. What is the primary therapeutic mechanism of action of HMG-CoA reductase
inhibitors (Statins) within hepatocytes?
A) Directly blocking cholesterol reabsorption in the brush border of the small
intestine
B) Activating peroxisome proliferator-activated receptor alpha (PPAR-alpha)
